6 results about "Protein S" patented technology

The present application belongs to the field of veterinary drugs, and provides a recombinant protein S-Trimer of an infectious bronchitis virus antigen and a subunit vaccine therefor. Provided in the present application is a recombinant protein S-Trimer of an infectious bronchitis virus antigen, wherein the recombinant protein S-Trimer of the antigen has an amino acid sequence as set forth in SEQ ID No. 4. Also provided in the present application is an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer described above. The present application provides a subunit vaccine for an infectious bronchitis virus, wherein the subunit vaccine comprises a pharmaceutically acceptable carrier and an immunogenic amount of the infectious bronchitis virus antigen.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and / or clotting.

The invention discloses an anti-MerTK antibody and an application of the anti-MerTK antibody. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, a chimeric antigen receptor, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody, and applications of the nucleic acid, the recombinant expression vector, the transformant, the chimeric antigen receptor, the antibody drug conjugate, the pharmaceutical composition or the kit in preparation of drugs for preventing and / or treating tumors. The antibody provided by the invention has high affinity, and can simultaneously block the interaction of the ligand GAS6-MerTK and the ligand protein S-MerTK, but does not block the interaction of the ligand TULP1-MerTK. And potential toxicity to the retina can be avoided when inhibition activity is exerted in vivo. In addition, the anti-human MerTK antibody provided by the invention can specifically and effectively inhibit phosphorylation of AKT in a Gas6-MerTK signal, and shows certain tumor inhibition activity in a mouse in-vivo model test.

A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from Table 1, 2 or 3 in a sample from a subject, where in the at least one protein may be selected from the list comprising: Beta-Ala-His dipeptidase, Apolipoprotein L1, Methanethiol oxidase, Vitamin K-dependent protein S, von Willebrand factor, Plasminogen, Selenoprotein P, Protein disulfide-isomerase A6 and Inter-alpha-trypsin inhibitor heavy chain H3, and (b) using the expression level to determine whether the subject has endometriosis.

Provided are a pharmaceutical composition for resisting infection with SARS-COV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-COV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and / or an adenovirus vaccine for preventing and / or treating an infection with SARS-COV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-COV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.

The application discloses application of a GmSAMS gene and protein in regulating soybean kernel quality, belongs to the technical field of genetic engineering, and particularly relates to application of the GmSAMS gene in regulating soybean kernel quality, wherein the nucleotide sequence of the GmSAMS gene is shown as SEQ ID NO. 1. The application can reduce the expression of a protein S-adenosylmethionine synthetase of the GmSAMS gene by silencing the GmSAMS gene, improve the protein content of soybean kernels, reduce the oil content of soybean kernels, reduce the total fatty acid content of soybean kernels, and make the soybean kernels smaller, so that the purpose of regulating the quality of soybean kernels is achieved.